GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Cyclically Adjusted Revenue per Share

Cellectis (Cellectis) Cyclically Adjusted Revenue per Share : $0.83 (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cellectis's adjusted revenue per share for the three months ended in Sep. 2023 was $0.003. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.83 for the trailing ten years ended in Sep. 2023.

During the past 12 months, Cellectis's average Cyclically Adjusted Revenue Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-01), Cellectis's current stock price is $2.56. Cellectis's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $0.83. Cellectis's Cyclically Adjusted PS Ratio of today is 3.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cellectis was 19.75. The lowest was 1.18. And the median was 3.44.


Cellectis Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Cellectis's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Cyclically Adjusted Revenue per Share Chart

Cellectis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.91 0.86

Cellectis Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.86 0.86 0.88 0.83

Competitive Comparison of Cellectis's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted PS Ratio falls into.



Cellectis Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cellectis's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.003/118.2600*118.2600
=0.003

Current CPI (Sep. 2023) = 118.2600.

Cellectis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 0.000 99.100 0.000
201306 0.000 99.700 0.000
201312 0.000 99.800 0.000
201406 0.000 100.180 0.000
201412 0.000 99.860 0.000
201503 0.288 100.170 0.340
201506 0.233 100.440 0.274
201509 0.241 99.950 0.285
201512 0.842 100.040 0.995
201603 0.222 100.020 0.262
201606 0.496 100.630 0.583
201609 0.315 100.340 0.371
201612 0.230 100.650 0.270
201703 0.188 101.170 0.220
201706 0.183 101.320 0.214
201709 0.170 101.330 0.198
201712 0.161 101.850 0.187
201803 0.168 102.750 0.193
201806 0.120 103.370 0.137
201809 0.021 103.560 0.024
201812 0.020 103.470 0.023
201903 0.024 103.890 0.027
201906 0.027 104.580 0.031
201909 0.200 104.500 0.226
201912 0.104 104.980 0.117
202003 1.180 104.590 1.334
202006 0.068 104.790 0.077
202009 0.145 104.550 0.164
202012 -0.211 104.960 -0.238
202103 0.597 105.750 0.668
202106 0.246 106.340 0.274
202109 0.183 106.810 0.203
202112 -0.324 107.850 -0.355
202203 0.037 110.490 0.040
202206 0.029 112.550 0.030
202209 0.004 112.740 0.004
202212 0.351 114.160 0.364
202303 0.003 116.790 0.003
202306 0.003 117.650 0.003
202309 0.003 118.260 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Cellectis  (NAS:CLLS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cellectis's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.56/0.83
=3.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cellectis was 19.75. The lowest was 1.18. And the median was 3.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cellectis Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Cellectis's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (Cellectis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (Cellectis) Headlines

From GuruFocus

Cellectis Announces Launch of Follow-On Offering

By Stock market mentor Stock market mentor 02-02-2023